Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Biotheus
company
About
Biotheus is a biotech company that focuses on the discovery and development of antibody-based therapeutics.
- 51 - 100
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $100M
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 2018
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$100M ¥100M
Biotheus has raised a total of
$100M ¥100M
in funding over 2 rounds. Their latest funding was raised on
Mar 2, 2021 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 2, 2021 | Series D | $100M | 1 | — | — | Detail |
| Jun 26, 2019 | Seed | ¥100M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Biotheus is funded by 2 investors.
Huajin Fund
and Zhuhai Huajin Asset
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series D |
|
|
— | Seed |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
